Iterum Therapeutics plc Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD from Q2 2017 to Q2 2024
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
Iterum Therapeutics plc quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from Q2 2017 to Q2 2024.
- Iterum Therapeutics plc Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending June 30, 2024 was -$4.97M, a 58.8% increase year-over-year.
- Iterum Therapeutics plc Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending June 30, 2024 was -$28M, a 50.5% increase year-over-year.
- Iterum Therapeutics plc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was -$37.8M, a 14.4% increase from 2022.
- Iterum Therapeutics plc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was -$44.1M, a 51.4% increase from 2021.
- Iterum Therapeutics plc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2021 was -$90.9M, a 77.2% decline from 2020.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Growth (%)